A Study of the TheraBionic P1 Device in Breast Cancer

The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.

Trial Details

NCT ID
NCT07218432
Phase
NA
Sponsor
Barbara Ann Karmanos Cancer Institute
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • TheraBionic P1 Device
Locations (sample)
  • Clarkston, Michigan, United States|42.73586,-83.41883
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Farmington Hills, Michigan, United States|42.48531,-83.37716
  • Flint, Michigan, United States|43.01253,-83.68746
  • Lansing, Michigan, United States|42.73253,-84.55553

Key Eligibility Criteria

  • Participant must have histologically proven invasive breast cancer that is HR (hormone receptor) positive and HER2 (Human Epidermal Growth Factor R…
  • Participant must have early-stage operable disease (stage I-II or III who have planned upfront surgery) and agree to definitive upfront surgery.
  • Participant must be available for at least two weeks of TheraBionic treatment prior to scheduled resection
  • Participant must have archival tissue available.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →